drugset / Trial / NCT03324061
Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
RandomizedParallel-groupOpen-labelOther
Summary
Clinical study designed to assess the plasma pharmacokinetic profile and tolerability of Fulvestrant for Injectable Suspension after a single IM dose of Fulvestrant for Injectable Suspension compared to the reference product, Faslodex in healthy female subjects.
Timeline
- Start
- 2017-11-30
- Primary completion
- 2018-07-12
- Completion
- 2018-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fulvestrant | Small molecule | 500 mg | Intramuscular |
Indications
No indication recorded.